Table Of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Prescription Trends (2024), by Region
5.3 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket) (2024)
5.4 Market Growth and Forecast (2024-2032)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Transthyretin Amyloidosis Treatment Market Segmentation By Therapy
7.1 Chapter Overview
7.2 Targeted Therapy
7.2.1 Targeted Therapy Market Trends Analysis (2020-2032)
7.2.2 Targeted Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Supportive Therapy
7.3.1 Supportive Therapy Market Trends Analysis (2020-2032)
7.3.2 Supportive Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Pipeline Therapy
7.4.1 Pipeline Therapy Market Trends Analysis (2020-2032)
7.4.2 Pipeline Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Transthyretin Amyloidosis Treatment Market Segmentation By Type
8.1 Chapter Overview
8.2 ATTR with Polyneuropathy (ATTR-PN)
8.2.1 ATTR with Polyneuropathy (ATTR-PN) Market Trends Analysis (2020-2032)
8.2.2 ATTR with Polyneuropathy (ATTR-PN) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 ATTR with Cardiomyopathy (ATTR-CM)
8.3.1 ATTR with Cardiomyopathy (ATTR-CM) Market Trends Analysis (2020-2032)
8.3.2 ATTR with Cardiomyopathy (ATTR-CM) Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Transthyretin Amyloidosis Treatment Market Segmentation By Disease
9.1 Chapter Overview
9.2 Hereditary Transthyretin Amyloidosis
9.2.1 Hereditary Transthyretin Amyloidosis Market Trends Analysis (2020-2032)
9.2.2 Hereditary Transthyretin Amyloidosis Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Wild Type Amyloidosis
9.3.1 Wild Type Amyloidosis Market Trends Analysis (2020-2032)
9.3.2 Wild Type Amyloidosis Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Transthyretin Amyloidosis Treatment Market Segmentation By Distribution Channel
10.1 Chapter Overview
10.2 Hospital Pharmacies
10.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
10.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Specialty Pharmacies
10.3.1 Specialty Pharmacies Market Trend Analysis (2020-2032)
10.3.2 Specialty Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Retail Pharmacies
10.4.1 Retail Pharmacies Market Trends Analysis (2020-2032)
10.4.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.5 Online Pharmacies
10.5.1 Online Pharmacies Market Trends Analysis (2020-2032)
10.5.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.2.3 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.4 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.5 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.6 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.7.2 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.7.3 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.7.4 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.8.2 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.8.3 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.8.4 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.9.2 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.9.3 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.9.4 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe Mobile Payment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.3.3 Europe Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.4 Europe Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.5 Europe Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.6 Europe Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.7.2 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.7.3 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.7.4 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.8 France
11.3.8.1 France Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.8.2 France Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.8.3 France Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.8.4 France Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.9.2 UK Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.9.3 UK Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.9.4 UK Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 ItalyTransthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.10.2 Italy Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.10.3 Italy Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.10.4 Italy Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.11.2 Spain Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.11.3 Spain Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.11.4 Spain Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.12.2 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.12.3 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.12.4 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.13.2 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.13.3 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.13.4 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.14.2 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.14.3 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.14.4 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.4.3 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.4 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.5 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.6 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.7.2 China Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.7.3 China Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.7.4 China Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.8.2 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.8.3 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.8.4 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.9.2 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.9.3 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.9.4 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.10.2 South Korea Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.10.3 South Korea Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.10.4 South Korea Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.11.2 Singapore Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.11.3 Singapore Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.11.4 Singapore Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.12.2 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.12.3 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.12.4 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.5.3 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.4 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.5 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.6 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.7.2 UAE Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.7.3 UAE Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.7.4 UAE Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.8.2 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.8.3 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.8.4 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.1.9 Qatar
11.5.9.1 Qatar Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.9.2 Qatar Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.9.3 Qatar Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.1.9.4 Qatar Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.10.2 South Africa Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.10.3 South Africa Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.10.4 South Africa Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Payment Type (2020-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.6.3 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.4 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.5 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.6 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.7.2 Brazil Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.7.3 Brazil Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.7.4 Brazil Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.8.2 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.8.3 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.8.4 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.9.2 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.9.3 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.9.4 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
12. Company Profiles
12.1 Alnylam Pharmaceuticals
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Pfizer Inc.,
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Ionis Pharmaceuticals
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 BridgeBio Pharma.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Prothena Corporation plc.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Akcea Therapeutics
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Eidos Therapeutics
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 SOM Biotech
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 AstraZeneca plc.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Alexion Pharmaceuticals
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
